Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Apricus Bioscience to market its over-the-counter (OTC) anti-itch drug Hydrocortisone-D.
Subscribe to our email newsletter
Hydrocortisone-D, which uses the company’s proprietary drug delivery technology NexACT, combines hydrocortisone with DDAIP.
The active ingredient in the cleared OTC drug, hydrocortisone, is an already approved anti-itch agent, and sold under several third party brand names like Cortizone (Chattem/Sanofi Aventis) and Cortaid (Johnson & Johnson).
Apricus chairman, president and CEO Bassam Damaj said this is the second clearance by the FDA of a drug containing Apricus Bio’s NexACT drug delivery technology, and as such, enhances their strategy of building out their OTC products division and creating a new revenue-generating portfolio for the company.